Intermountain Heart Institute at Intermountain Medical Center

(801) 507-4701Map5121 S. Cottonwood StreetMurray, UT 84107
Illustration of HVAD Pump
Intermountain Heart Institute
Heart Failure & Transplant
(801) 507-4000
Artificial Heart
(801) 507-LVAD

The following clinical trials are currently enrolling patients. For more information please contact us.

Heart Failure Clinical Trials

TRIAL: CARRESS
Long Title: Cardiorenal Rescue Study in Acute Decompensated Heart Failure
Principal Investigator: A. G. Kfoury, MD
Sponsor: National Heart, Lung, and Blood Institute (NHLBI) and Duke University/Duke Clinical Research Institute
Description: The purpose of this study is to evaluate the safety and effectiveness of ultrafiltration for the treatment of patients with persistent congestion (fluid buildup) and cardiorenal syndrome (abnormal kidney function). Patients eligible to participate in this trial must have decompensated heart failure and the onset of cardiorenal syndrome.

TRIAL: PCN
Long Title:
Immune Activation and Myocardial Recovery in Peripartum Cardiomyopathy
Sponsor: National Institutes of Health and the University of Pittsburgh
Principal Investigator: Rami Alharethi, MD
Description: Peripartum Cardiomyopathy (PPCM) is a very rare condition that causes women to have serious heart problems during pregnancy or shortly after giving birth. This study is designed to determine what causes PPCM; it will evaluate immune reactions, genetic make-up, and hormonal fluctuations in patients with this condition. Researchers hope that once the causes are known, treatments and preventative strategies can be used to assist patients and their families.

TRIAL: LAPTOP- HF
Long Title:
Left Atrial Pressure Monitoring to Optimize Heart Failure Therapy Study
Sponsor: St. Jude Medical
Principal Investigator: Rami Alharethi, MD
Description: This trial is designed to test if an implanted left atrial pressure monitoring device is safe and effective at preventing heart complications. The device lets patients and their doctors know how their heart is performing on a regular basis. It is hoped that this information will allow medical care providers and patients to respond quickly to any changes that may occur. Patients who have been diagnosed with heart failure and have a history of cardiomyopathy for at least 6 months may be eligible for this study.

TRIAL: RELAX
Long Title:
Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Diastolic Heart Failure
Principal Investigator: A.G. Kfoury, MD 
Sponsor: National Heart, Lung, and Blood Institute (NHLBI) and Duke University/Duke Clinical Research Institute
Description: Sildenafil is a drug that increases the supply of blood to the lungs and reduces the workload of the heart. We are testing Sildenafil in patients with diastolic heart disease to see if it will improve their ability to exercise and their quality of life. You may be eligible to participate in this study if you have heart failure and have been on stable medical therapy for at least 30 days.

TRIAL: ROSE
Long Title:
Renal Optimization Strategies Evaluation in Acute Heart Failure
Principal Investigator: A.G. Kfoury, MD 
Sponsor: National Heart, Lung, and Blood Institute (NHLBI) and Duke University/Duke Clinical Research Institute
Description: The purpose of this study is to evaluate the safety and efficacy of adjuvant renal-protective therapies with low dose Dopamine and low dose Nesiritide, added to optimal diuretic dosing, in patients with acute heart failure. Patients hospitalized for acute heart failure may qualify for this study.

Artificial Heart & LVAD Clinical Trials

Trial: ENDURANCE
Long Title: A Clinical Trial to Evaluate the HeartWare® Ventricular Assist System
Principal Investigator: Bruce Reid, MD
Sponsor: HeartWare, Inc.
Description: This study evaluates the use of the HeartWare Ventricular Assist System for Destination (permanent) Therapy patients with advanced heart failure. Participants receiving this device may not be candidates for heart transplant.

Trial: CentriMag – Failure to Wean
Long Title:
Levitronix CentriMag VAS Failure-to-Wean from Cardiopulmonary Bypass
Principal Investigator: Stephen E. Clayson, MD
Sponsor: Levitronix LLC
Description: This study is specifically designed for patients who are unable to come off cardiopulmonary bypass after their cardiac surgery. This study evaluates the CentriMag device which helps support patient's hearts while they are recovering in the hospital. All participants in this study must be at least 18 years of age and need heart support after their cardiac procedure.

Trial: CentriMag – RVAS
Long Title:
CentriMag RVAS U.S. Post Approval Study
Principal Investigator: Stephen E. Clayson, MD
Sponsor: Levitronix LLC
Description: This study evaluates the CentriMag device when used to support the right side of the heart. The device helps support patients who develop right heart failure. All participants in this study must be at least 18 years of age and need heart support for right heart failure.

Trial: FREEDOM
Long Title:
SynCardia Freedom Driver System Study
Principal Investigator: Stephen E. Clayson, MD
Sponsor: SynCardia Systems Inc
Description: The purpose of this study is to determine if the Freedom Driver System (a pneumatic pump) will sufficiently support the Total Artificial Heart (TAH-t) in clinically stable patients. The second purpose of this study is to see if non-medical people, the patients and caregivers, can be trained to manage the Freedom Driver System safely outside the hospital while the patient waits for a heart transplant. In order to be in this study, you must be implanted with the TAH-t and your health must have stabilized after the surgery so that your doctor feels that it may be possible for you to go home while implanted with the TAH-t and supported by the Freedom Driver.

Title:
Syncardia temporary Total Artificial Heart (TAH-t) Post Market Surveillance Study
Principal Investigator:
Stephen E. Clayson, MD
Sponsor: SynCardia Systems, Inc.
Description: This study is being conducted to evaluate whether the patient results achieved when the temporary Total Artificial Heart (TAH-t) is implanted at trained hospitals are the same as the patient results that were achieved during the clinical trial that led to the TAH-t being approved by the FDA. In order to participate in this study, patients must be implanted with the TAH-t. This is a registry study which involves historical data collection, neurology tests and two brief follow up phone conversations after patients have received a heart transplant.

Copyright © , Intermountain Healthcare, All rights reserved.